Harm Reduction at the Crossroads Drugs, drug policy, harm reduction: A reality check International AIDS Conference July 25, 2018 Amsterdam Daniel.

Slides:



Advertisements
Similar presentations
The need to challenge unhealthy drug policies to improve drug treatment Dr Chris Ford, Holly Catania and Rebecca Murchie IDHDP.
Advertisements

Saving lives, changing minds. Collaborative TB/HIV services for people who use drugs The experience of Red Cross / Red Crescent Lasha Goguadze.
Bringing Opioid Substitution Treatment to scale Dr. M. Suresh Kumar Inter-country Consultation on Preventing HIV among IDUs Scaling Up: From Evidence to.
Harmonizing public health and public safety in a politically conservative environment Joëlle Rabot Field Coordinator Collectif Urgence.
“Humanitarian Action” The Saint-Petersburg Charitable Foundation for Medical and Social Programs HAF.
Topic 3 Strategies that help reduce the transmission of HIV Slide 3.1.
Presentation ‘Developing positive working relationships between Health and Law Enforcement Agencies’
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
+ Opioid Substitution Therapy for Injecting Drug Users: Scale versus Quality WORKSHOP “OST in Developing Countries: A Primer” Atul Ambekar, Alok Agrawal.
…at what cost ? …at what cost ?. Ten year review:  Law enforcement at the expense of public health and human rights  Major HIV epidemics among IDU 
-Focus on evidence-based and current best practice -To assist law enforcement and other uniformed services build their capacity and enhance their role.
Washington D.C., USA, July 2012www.aids2012.org Addressing the intersection of criminalisation, discrimination and stigma Susan Timberlake Chief,
How to survive in a non-supportive environment: Experience from Russia Ivan Varentsov (Andrey Rylkov Foundation) AIDS 2014, Melbourne.
 Insufficient Reliable data in this region  Estimated people living with HIV  The number of new HIV infections in the region increased.
HIV, Drug Policy and Harm Reduction. Outreach in Moscow, Russia,1998.
Harm Reduction.
HIV, drugs and the legal environment Steffanie A. Strathdee (University of California San Diego, La Jolla, CA, USA), Leo Beletsky (Northeastern University.
TI for IDUs Sexual IDUBlood Perinatal Unidentified Routes of HIV Transmission SENTINEL SURVEILLANCE 2006 HIV infection in India.
Building Trust With the Injection Drug Community Megan Hatta, RN.
Medical Professionalism and its Relationship to Public Health: Physician Advocacy and State Public Health Policy Thomas Kellogg Program Officer and Advisor.
“Getting to Zero” UNAIDS Strategy Dr. Paul De Lay, Deputy Executive Director, Programme UNAIDS.
A global perspective on scaling up harm reduction 2 nd National Harm Reduction Conference, Ukraine, March 2007 Dr Jos Perriens, Director Prevention.
Washington D.C., USA, July 2012www.aids2012.org Human rights as a key component of harm reduction strategy targeting people using drugs in Morocco.
Australia’s Drug Policy Greg Denham Nossal Institute for Global Health.
Economic and policy dimensions of HIV in Eastern Europe and Central Asia David Wilson and Nicole Fraser, Global HIV/AIDS Program, World Bank David Wilson,
Washington D.C., USA, July 2012www.aids2012.org Alternatives to NSEPs: community-based initiatives Providing access to syringes in the politically.
Paradoxes and Problems in Preventing HIV Infection among Injecting Drug Users and Their Sexual Partners in Eastern Europe and Asia Don C. Des Jarlais,
1 People who use drugs, HIV, and human rights The Lancet : HIV in people who use drugs Vienna, 20 July 2010 Ralf Jürgens Joanne Csete, Joe Amon Steven.
School of Public Health and Community Medicine How policies and repressive law- enforcement fuel the HIV epidemic among people who inject drugs Professor.
International Conference on AIDS and STIs in Africa ICASA ‘ Patients Not Criminals’ - Harm Reduction Responses and Policy Reform in Kenya By Dr.
Harm reduction evidence: Eastern Europe and Central Asia Raminta Stuikyte Central and Eastern European Harm Reduction Network.
Moving from a commodity approach: “Fund some of everything” or “Fund what is comfortable” to An Investment approach: “Fund evidenced-based activities.
Harm reduction saves the lives of millions: will Eastern Europe take the chance? Andriy Klepikov, Intenational HIV/AIDS Alliance in Ukraine 24 th of June,
NOUS SOIGNONS CEUX QUE LE MONDE OUBLIE PEU A PEU Starting needle exchange programming for injecting drug users (IDUs) in Temeke District, Dar-es- Salaam,
International Harm Reduction Development Program: Lessons learned
MODULE 3 Harm reduction advocacy
IAS Satellite Session 25th July 2017 Daniel Were, PhD
The Aviator Hotel – South Africa Uganda Harm Reduction Network (UHRN)
Dr. Monica Beg, Chief, HIV/AIDS Section, UNODC
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
Fabienne Hariga Senior Adviser, HIV/AIDS Section
MODULE 2 Effective drug policy What needs to change?
Effective HIV & SRH Responses Among Sex Workers and other Key Populations Module 1: National Data.
Understanding a Harm Reduction Approach to Drug Interventions
Needle and syringe exchange and working with injecting drug users
Harm reduction: decriminalising drug use in Asia
McLean Hospital Division of Alcohol and Drug Abuse
Community Action on Harm Reduction (CAHR) Programme
Summary Report: Management of Hepatitis C in Prisons
Steve Alsum The Grand Rapids Red Project
DRUG USE WORLDWIDE AND HIV
Coverage of HIV and HCV prevention interventions for people who inject drugs Dr Sarah Larney, Senior Research Fellow.
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Towards a Conducive Legal and Structural Environment
10 by 20 campaign: Strategies for tracking and rebalancing investment in drug law enforcement and harm reduction Emily Rowe, Harm Reduction International.
Global Village Debate This house would ban information dissemination on safe injecting practices, and ban the provision of clean and sterile injecting.
Global Optimization of the Response to HIV
Ivan Varentsov Amsterdam. AIDS 2018.
The HIV Epidemic among People who Inject Drugs
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
The prevalence of non-fatal overdose among people who inject drugs
Strategies for sustainable financing of harm reduction:
Indonesia Harm Reduction Funding Tracking
Myanmar Last Update: November 2014.
National Drug and Alcohol Research Centre, School of Public Health
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review 
Campaigning to redirect resources from drug control to harm reduction:
Beyond drug criminalisation: Why, what and how?
No conflicts of interest
Human Dignity and Harm Reduction
Presentation transcript:

Harm Reduction at the Crossroads Drugs, drug policy, harm reduction: A reality check International AIDS Conference July 25, 2018 Amsterdam Daniel Wolfe Director, International Harm Reduction Development Public Health Program Daniel.wolfe@opensocietyfoundations.org

How are we doing?

HRI, Global State of Harm Reduction 2016, https://www. hri

Less than 1% of PWID live in countries with high coverage of both NSP and OST (>200 needle-syringes distributed per PWID and >40 OST recipients per 100 PWID). Larney S, Peacock A, Leung J, Colledge S et al, 2017

Not how much harm reduction, but how framed?

Framing bias #1—Control and Contain Saying “health issue rather than criminal issue” not enough Form and language of public health interventions often echo those of enforcement Photo: Hans-Jurgen Burkard Fingerprinting for methadone treatment; names and IDs for needles and syringes; drug user registries; biometrics for survey duplication—these are among the practices in the countries we singl eout for progress in harm reduction. Those of us trained in public health would do well to listen to our own language to hear what

Universal testing

Surveillance

Treatment for All

Framing bias #2—Biotechnologies Irony is that those of us working in harm reduction know the limits, since we have a technology that works extremely well to reduce HIV infections to zero--and yet almost never employ it.

Framing Bias #3: HIV (and abstinence) as outcomes of interest Even if you think, as I do, that it's absolutely critical, improtant to see beyond needles and veins.  Stimulant use!  Multiple drug use!  Overdose!  These are what shape people's lives, and so what we if we are interested in saving people's lives, need to attend to.   Law enforcement doesn't find drug users hard to reach...precisely because they don't make these distinctions (and have 24 hour outreach)

Under our Skin? A future joining all three biases?   All potentially useful tools, but also easily abusable by those who would remove patient choice in the name of patient (and provider) convenience.  Noticeable that naltrexone--more than 100 times more expensive than methadone--being used now even in countries where resources are limited

Law enforcement as new market? , and that the manufacturer has targeted criminal justice officials rather than doctors as a prime market. .

Back to Basics People’s needs, not system needs   Can't work around people who use drugs--need to work with them.  This means harm reduction is not a set of interventions, not a philosophy. Not evidence of HIV infections averted, but that joins the narratives of love, safety, family and community protection. People’s needs, not system needs Human values, not health interventions Photo: Mainline

Dynamic and powerful, not static and contained Thank you for your attention!